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ABSTRACT
For the majority of patients with end-stage kidney failure
(ESKF) replacement of excretory renal function by dialy-
sis or transplantation (RRT) can extend life and alleviate
symptoms. Historically, the availability of RRT has been
insufficient and this remains the case for much of the
world. However, RRT is now widely available in health-
care systems of higher income countries. Increasing num-
bers of elderly patients are developing ESKF. RRT in
this population is largely by dialysis, comorbidity is high
and life expectancy short. Evidence of effectiveness cou-
pled with the burden of treatment among these individu-
als has raised concerns that health services in high-income
countries may have moved from an era of unmet need
into one of potential over-treatment. Alongside the
requirement to make treatment more patient-centered, this
has driven the development of comprehensive conserva-
tive care as an alternative approach for older comorbid
individuals with ESKF, with the potential for acceptable
symptom control and reduced treatment burden. This
paper provides a largely UK-perspective on treating
ESKF without RRT. Emphasis is on the need for high-
quality evidence to inform treatment decisions. Complexi-
ties of defining, delivering and improving treatment of
ESKF without dialysis care are explored. Quantitative
and qualitative evidence are summarized and the relation-
ship with palliative and terminal care examined. A frame-
work is suggested for classifying management of ESKF
and recommendations made to improve delivery of
nondialysis care in the future. For patients with a poor
prognosis, such treatment may not result in significantly
different survival or quality of life when compared with
dialysis. There is a key need to generate the best possible
evidence of person-centered health outcomes associated
with the various treatment options for ESKF and to pre-
sent this to patients in a balanced, personalized way that
allows them to make the treatment decision most appro-
priate for them.
Renal replacement therapy (RRT) using dialysis
has been available for the treatment of end-stage
kidney failure (ESKF) from the 1960s. Early tech-
nology and availability meant it was offered only to
those with the best prognosis. Infamously, this led
to the development of committees responsible for
directing limited capacity toward those felt most ‘el-
igible’ (1). RRT remains an expensive therapy lar-
gely unavailable to the populations of lower income
countries (2,3). In higher income countries, succes-
sive health policy changes have seen progressive
service expansion, and capacity no longer restricts
dialysis provision. Improvement in outcomes from
long-term dialysis allows patients with ESKF to live
longer (4). Despite a plateauing of RRT incidence
in many countries, the prevalent population receiv-
ing dialysis continues to expand (5). Compounded
by the limited supply of transplant organs, the pop-
ulation with ESKF has shifted from largely work-
ing-age people with single organ disease to one
increasingly comprising older, more comorbid indi-
viduals, predominantly receiving in-center hemodial-
ysis (6). With the United Kingdom general
population aged over 65 predicted to increase by
60%, from 10.3 to 16.9 million by 2035 this trend
seems set to continue (7).
As people live longer and die with chronic, non-
communicable disease, cultural attitudes toward ill-
ness, treatment and death have changed (8). Illness
and dying are perceived as preventable, even in an
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individual’s older and last years. In the United
Kingdom, almost half of adults die in a hospital
bed (9) and about one in five Americans die during
a hospitalization including intensive care (10).
Patients approaching the end of life are frequently
in receipt of polypharmacy (11). Revolutionary
advances in medicine have been replaced by gradual
refinement of practice and development of increas-
ingly expensive, higher technology treatments with
slighter, incremental benefits to the individual. In
parallel, there has been a practice shift away from
paternalistic medicine toward increasingly holistic
and patient-centered care. Shared decision-making
empowers individuals and their carers to make
choices about what care they want based on honest,
open disclosure of the known benefits and risks of
proposed treatment options (12). The model of ‘cu-
mulative complexity’ recognizes a requirement for
individuals to cope with demands of illness and
treatment, and that incapacity to cope with these
demands can lead to further negative health out-
comes (13). So called ‘minimally disruptive medi-
cine’ advocates a pragmatic approach to therapeutic
recommendations in an effort to minimize treatment
burden on patients and their carers, especially
those with major comorbidity or approaching the
end of life (14).
Preparation for RRT involves planning for in-
center hemodialysis for most older comorbid
patients with advanced chronic kidney disease
(CKD) and guidelines promote education and vas-
cular access well in advance of ESKF (15–17). The
benefits of this approach are available only to those
who survive to start RRT, whereas every patient is
exposed to the burdens and associated risk of harm
of preparing for dialysis. Some individuals elect for
the symptoms and complications of their kidney dis-
ease to be managed without RRT. Terminology for
this approach includes ‘comprehensive conservative
care’ (CCC—used in this paper) (18), ‘nondialysis
care’ and ‘conservative kidney management’ (19,20).
The comparative effectiveness of dialysis and CCC
has been studied in countries which have formally
introduced such pathways and is discussed in more
detail below.
Historically, the UK RRT program has had
lower uptake than many other countries with com-
parable populations, although rates have increased
(21). It is not easy to disentangle the role of ration-
ing (implicit or explicit) in this, as compared with
careful and appropriate use of treatment. Neverthe-
less, CCC is more accepted in the United Kingdom
than in many other developed countries, affording a
key perspective from which to examine the evidence
base for its appropriate and effective development.
In this paper, the complexities surrounding defini-
tion and identification of ESKF are examined.
Pathways of CKD care are illustrated and a treat-
ment classification advanced. Quantitative and qual-
itative evidence of outcomes and experiences of
CCC and dialysis are summarized. Approaches to
the development of higher quality evidence to
support clinicians and patients in making better-
informed decisions about how to plan for ESKF
are proposed.
Incidence and Prevalence of ESKF
Robust, population-based data to describe ESKF
epidemiology are unavailable (Fig. 1). RRT reg-
istries only systematically collect individual patient
outcomes and describe the natural history of RRT-
treated ESKF. RRT receipt is influenced by levels
of detection of advanced CKD, referral and accep-
tance on to RRT. Internationally, RRT treatment
has been increasing steadily over the last few dec-
ades, although rates in higher income countries
have stabilized more recently (5). While this
increase is substantially due to population ageing,
rising prevalence of diabetes and decline in compet-
ing mortality risk from cardiovascular disease, it
also reflects expansion in dialysis services and
changing referral and acceptance rates, highlighting
the inadequacy of studying ESKF epidemiology
using RRT receipt. Hospitalization data are an
invalid measure of ESKF incidence or prevalence
because they relate only to known treated inpatient
cases and lack clarity due to insufficiencies in Inter-
national Classification of Diseases coding. Beyond
reach of routinely captured data are those with
undiagnosed ESKF who have never had blood
tests. Mortality data are unreliable because of
under-ascertainment of renal disease on death cer-
tificates (22). Cohort studies suggest the incidence
of CKD has been relatively stable in comparison
with growth in RRT-treated ESKF (23), but CKD
registries are not widespread.
RRT treatment in the United Kingdom has been
rising fastest among those aged over 75 years, who
now account for almost a quarter of new dialysis
patients (21). Comorbidity is prevalent and
increases with age (6). Of patients aged over 65
commencing dialysis, 82% receive hemodialysis (21)
and transplantation is not an option for most, espe-
cially once aged over 75 (24). Fifty-five percent of
65–74 year olds and 40% of those aged 75 or over
survive 3 years. However, 30% of over-85 year olds
die within 1 year of commencing dialysis (4). Early
mortality is probably underestimated due to incom-
plete registry data for patients receiving dialysis fol-
lowing acute decompensation (25) (Fig. 1). In the
United Kingdom, 19% of deaths within 1 year of
commencing dialysis among patients aged over
65 are due to withdrawal from treatment and rates
are rising (4).
For much of the globe, there remains a deficiency
of organized data on the incidence and prevalence
of ESKF, provision for its treatment and its out-
comes (26). Considerable portions of the world pop-
ulation have no access to specialist renal services.
Once ESKF develops individuals are likely to either
remain undiagnosed, or be diagnosed and unable to
access RRT. Reported global incidence rates for
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RRT-treated ESKF range from 12 to 455 (median
130) per million population (3). This variation
reflects factors including population health and
demography including disease burden. However,
macroeconomic and service factors such as Gross
Domestic Product spent per capita, percentage of
Gross Domestic Product spent on health care, dialy-
sis reimbursement rate and the private for profit
share of dialysis provision are more strongly associ-
ated (3). Work needs to be done to join up these
various sources of data on CKD in different settings
and gain a full picture of the care of people with
CKD and ESKF, though the solutions are likely to
have to be specific to the databases and information
governance laws in the different countries.
Provision of Nondialysis Care
While CCC is recognized and delivered widely
(19,20,27–29), the international population of indi-
viduals receiving CCC has not been evaluated.
Scope and practice patterns of CCC in the United
Kingdom have been systematically recorded (20). A
nondialysis pathway was available in nearly every
UK renal unit. Data on the number of older
patients on a nondialysis pathway were available
for almost half of units, and varied greatly from 4
to 152, often but not always reflecting the total pop-
ulation of patients in a unit. Data on symptomatic
older patients on a nondialysis pathway, perhaps a
better gauge of CCC delivery, also varied widely,
ranging from 1 to 50 patients per unit. Approxi-
mately one in five units had clinics exclusively for
patients on a nondialysis pathway and this was clo-
sely related to whether they had staff primarily
responsible, and funding, for nondialysis care.
Unlike RRT preparation and delivery, CCC receives
no automatic payment by results within UK health-
care tariffs. Linkage with primary care data was
available for a small number of units and suggested
that most (94%) individuals with CKD stage 5 were
known to renal services. What degree of triage
occurred before laboratory testing in primary care
was not examined.
The very wide variation in numbers of patients
receiving nondialysis care (20) is likely to reflect, in
part, the lack of an agreed definition of the pathway
and highlights the need for a uniform terminology
(19). Variation also reflects local CKD identifica-
tion, referral and treatment patterns along with
deviation in population demographics. The trend
over the past decade has been for increasing invest-
ment in such services (30) and some units have
shown considerable investment in staff time and
dedicated processes to support patients on a
nondialysis pathway.
In 2013, Kidney Disease: Improving Global Out-
comes (KDIGO), in partnership with the Interna-
tional Society of Nephrology (ISN), held a
conference to develop consensus on the application
of palliative care in CKD (18). The lack of clear
Fig. 1. Pathway for people with advanced chronic kidney disease in primary or secondary care with reference to potential data sources
on numbers affected and outcomes. Black/gray shaded boxes represent areas where no/limited data exist. CKD chronic kidney disease,
CCC comprehensive conservative care, RRT renal replacement therapy.
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definitions was felt to have constrained both treat-
ment and research for this population. A definition
of CCC was proposed including all aspects of care
for individuals with ESKF managed without RRT
(Table 1). The conference represented a milestone in
the care of patients with or approaching ESKF
and prepared the ground for development of an
evidence base from which care and outcomes can
be improved.
Treatment of Individuals with or Approaching
ESKF: A Proposed Terminology
An agreed terminology for treatment of those
with or approaching ESKF is necessary to facilitate
communication with patients, carers, clinicians and
policy makers. In research and policy, evidence,
guidance and direction can be developed only once
patient populations are defined. The KDIGO/ISN
conference defined supportive care and CCC, but
did not produce a classification of treatment path-
ways where both RRT and CCC are available (18).
A classification is proposed in Fig. 2.
The proposed classification uses ‘ESKF’ to
describe sufficiently impaired kidney function such
that individuals are in receipt of either RRT or
CCC (after a putative point similar to an indication
to start RRT). Estimated glomerular filtration rate
(eGFR) associates imperfectly with disease severity
and cannot alone identify ESKF (31). Serum crea-
tinine reflects body composition as well as renal
function and loses precision as a marker of kidney
function in individuals with low muscle mass, mal-
nourishment, or at extremes of age (32). Some indi-
viduals with an eGFR as high as ≥15 ml/minute/
1.73 m2 have substantial symptoms or biochemical
complications and a small number initiate dialysis
at this stage (33). Many patients with eGFR <
15 ml/minute/1.73 m2 have acceptable fluid balance,
biochemistry and symptom control and stability of
kidney function.
Initiation of dialysis is not an unambiguous mar-
ker of ESKF. Initiating dialysis preemptively does
not provide benefit over waiting for an indication to
commence treatment (34). Symptoms, hyperkalemia
and fluid overload increase with declining kidney
function, but are not categorical phenomena—the
risk of sudden death, for example, increases pro-
gressively with rising serum potassium concentration
(35). Individuals (36) and their clinicians (37) weigh
potential benefits and burdens of treatment differ-
ently depending on personal preferences and values
and despite similar disease profiles, may initiate
dialysis—thus acquiring a label of treated ESKF—
at different times. Some will consider the benefits of
dialysis insufficient to outweigh the burdens and
choose nondialysis care (36). The point at which
such individuals have progressed from nondialysis
preparation to CCC may be difficult to identify
with precision. The proposed classification recog-
nizes the difference between individuals who are not
planning for RRT if ESKF develops and others
receiving CCC who would be undergoing dialysis if
that had been the chosen mode of care. However,
the dividing lines are indistinct, reflecting gradual
progression of disease, plasticity of decision-making
and the elusiveness of a definition for ESKF.
Decision-making is a process, not an epiphany
and this is reflected by the ability for patients to
move freely between the pathways, both at prepara-
tory and ESKF phases. Individuals presenting late
to renal services (Fig. 1) may develop ESKF with-
out being on either pathway and need to elect for
RRT or CCC at short notice.
Access to supportive care, advance planning and
palliative services should not be influenced by which
pathway a patient has chosen. As comorbidities
develop and an end of life phase approaches, care
may become progressively palliative on either path-
way and some patients receiving RRT may choose
to withdraw from dialysis. A greater proportion of
patients opting for CCC may already be at this
stage, but supportive care is a component of both
pathways as depicted in Fig. 2.
Comparing Outcomes between RRT and
Nondialysis Care
Tables 2 and 3 summarize key studies that have
compared the outcomes of patients receiving
nondialysis and RRT care. All have been observa-
tional in design, and with only three prospective
cohorts (29,38,39). Most have been single center
and from the United Kingdom, including three
from the same unit (38,40,41). The cohorts are
small, with only four including over 100 patients on
a nondialysis pathway. In total, 913 patients receiv-
ing nondialysis care were included. There are
methodological issues with the comparisons which
include: dealing with selection bias in allocation
(treatment by indication) and residual confounding;
identification of a start time for survival analysis
with long lead times in advanced CKD (and poten-
tial for lead time bias); exclusion criteria; uncertain
disease progression and prognosis in individuals
TABLE 1. Definition of comprehensive conservative care (CCC)
following the KDIGO Controversies Conference on supportive care
in chronic kidney disease (18)
CCC is planned holistic patient-centered care for patients with
CKD stage five including the following
• Interventions to delay progression of kidney disease and
minimize adverse events or complications
• Shared decision-making
• Active symptom management
• Detailed communication including advance care planning
• Psychological support
• Social and family support
• Cultural and spiritual domains of care
CCC care does not include dialysis.
CKD, chronic kidney disease.
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approaching ESKF; and variation in threshold for
RRT initiation between individuals, units and coun-
tries; cross-over between pathways and failure of
intention to treat analysis, and limited outcome
data.
Patients on a nondialysis pathway tended to be
older, more comorbid and have poorer functional
status (38,41–43), although this was not found in all
studies (39). Selection bias was addressed by restric-
tion or multivariate analysis including propensity
scoring (see Table 3). However, residual confound-
ing was a problem given the limited set of routinely
available variables in retrospective studies from
which adjustments can be made. There was typically
no adjustment made for functional status, frailty,
malnutrition, or cognitive impairment.
Identifying equivalent time points for individuals
on RRT and nondialysis pathways is necessary for
survival comparisons. Approaches to start time allo-
cation have included time of recording of decision-
making (intention to treat), estimating a putative
eGFR indicating ESKF and its timing in those on a
nondialysis pathway, and time of reaching a thresh-
old eGFR (see Table 2). Time of decision-making
fails to distinguish patients in a preparatory phase
from those in receipt of CCC and treatment
decisions may be made at different times among
those who choose RRT and nondialysis pathways.
Most studies excluded individuals first presenting to
renal services with an eGFR <10–15 mls/minute
on the grounds there was little time for decision-
making and high use of RRT in this group. Such
patients are often older and more comorbid and are
likely to have poor outcomes. The limitations of
eGFR as a marker of ESKF have already been out-
lined. Outcome data available were largely restricted
to survival, with a lack of cause of death statistics
to inform the role of direct death from ESKF in
those treated with CCC. Only three studies investi-
gated quality of life (29,38,39).
Compared with patients of the same age receiv-
ing dialysis, there was a survival disadvantage
associated with nondialysis care, but this dimin-
ished and even disappeared when comparison was
restricted to patients with high comorbidity or on
multivariate analysis (40,43–46), though this was
not found in all studies (38,47). Patients receiving
nondialysis care were more likely to die out of
hospital, with palliative care input, and less likely
to have an ‘over-medicalised’ death (41,43,45,48).
The patients receiving RRT, who were largely
treated with in-center hemodialysis, had greater
Fig. 2. Proposed classification of treatment of patients with or approaching ESKF. Left: conceptual framework from the KDIGO Con-
troversies Conference on Supportive Care in Chronic Kidney Disease(18). Right: RRT (upper) and nondialysis (lower) preparation path-
ways. Individuals with advanced CKD who anticipate commencing RRT if/when ESKF develops are classified as receiving ‘RRT
preparation’. Those who opt not to prepare for RRT are classified as receiving ‘nondialysis preparation’. In some, symptoms or biochemi-
cal abnormalities trigger RRT initiation (A). From this point, such individuals are classified as having ESKF and receiving RRT. At an
equivalent point (B), patients who choose not to commence RRT should be classified as having ESKF and receiving CCC, although identi-
fying this ‘putative dialysis’ point in practice is difficult (see text). Many patients will die before ESKF develops (C). Patients can move
freely between the pathways, during both preparatory and ESKF phases (double arrows). All patients are eligible for supportive care as
defined by the KDIGO guideline, though supportive needs may be greater among the nondialysis group (curved areas). CKD, chronic kid-
ney disease; RRT, renal replacement therapy; CCC, comprehensive conservative care; ESKF, end-stage kidney failure.
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TABLE 3. Outcomes in studies comparing comprehensive conservative care (CCC) and dialysis
Study
Univariate survival
CCC vs. dialysis Adjusted survival Hospitalization Quality of life Other outcomes
Joly, 2003
(42)
Median survival
8.9 months vs.
28.9 months
p < 0.001
1 year survival 29%
vs. 74%
Smith, 2003
(41)
Survival significantly
worse for CCC
group
Survived slightly
longer (2 months)
if switched from
CCC to dialysis vs.
continuing CCC
Cox proportional
hazard not
significant for CCC
intended and then
dialyzed vs. CCC
intended and not
dialyzed
More deaths in CCC
group were at home or
in a hospice
(p < 0.001)
Murtagh,
2007 (44)
Median time to
death or study end
540 days vs.
588 days p < 0.001
1 year survival 68%
vs. 84%
No difference in
survival if
comorbidity grade
2 especially if had
ischemic heart
disease
Significant
predictors:
CCC vs. dialysis
Ischemic heart
disease
Carson, 2009
(48)
Median survival
13.9 vs. 37.8 months
p < 0.01
None Hospital days
16 CCC vs. 25
hemodialysis per
patient year
Place of death at home
odds ratio for CCC
4.15 (1.67–10.25)
Teo, 2010
(47)
1 year survival
69% vs. 22%
peritoneal dialysis
and 20%
hemodialysis
Cox proportional
hazard CCC HR
2.29 (1.16–4.45)
adjusted age sex,
race, LV ejection
fraction, therapy
center
Mean number of
admissions 2.63
CCC vs. 3.45
hemodialysis vs.
3.2 peritoneal
dialysis (not
significant)
Chandna,
2011 (40)
Median survival in
those age >75 and
low comorbidity
29.4 vs. 36.8
(p = 0.03)
High comorbidity
20.4 vs.
25.8 months (not
significant)
Cox proportional
hazard model in
age >75
RRT pathway
survive 4 months
longer (not
significant)
Adjusted for age,
gender
comorbidity,
diabetes
Da Silva-
Gane, 2012
(38)
Median survival
913 vs. 1317 days
(vs. HD only)
Adjusted hazard
ratio for
hemodialysis vs.
CCC 0.47 (0.2–1.1)
p = 0.08
Adjusted for
comorbidity,
performance status,
age, physical
health component
of SF-36 and
propensity score
Quality of life
summary over
time:
No differences over
time in quality of
life assessments,
depression or
anxiety
Life satisfaction fell
at dialysis
initiation below
levels in CCC
group, which were
stable
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hospitalization rates and longer time spent in hos-
pital compared with those receiving CCC
(43,47,48), except in one study of patients receiv-
ing peritoneal dialysis, where the reverse was
found (45). In the three studies that examined
changes in quality of life (29,38,39), there were
some baseline differences with lower scores in
patients on a nondialysis pathway, notably in
terms of their physical health. However, quality of
life was more stable over time in those receiving
nondialysis care in contrast to those who started
dialysis, where an adverse impact on burden of
disease and life satisfaction was seen, with no
apparent quality of life gained.
Table 3. (Continued)
Study
Univariate survival
CCC vs. dialysis Adjusted survival Hospitalization Quality of life Other outcomes
Hussain,
2013 (43)
Survival at 1 year
58% vs. 72%
Survival on RRT
greater from time
of eGFR 20,15 or
12
RRT survival
advantage became
non-significant in
older age (>80) or
WHO Performance
score >3, and
much reduced if
more comorbid
RRT group at
increased risk of
hospitalization
relative risk 1.6
(1.1–2.1) p < 0.05
76% CCC accessed
community palliative
care, 0% RRT
CCC group had greater
chance of death
outside hospital
(though high levels of
missing data)
Seow, 2013
(39)
No difference in
CCC or RRT
quality of life
trajectories
(Kidney disease
specific Short form
36) after
adjustment, except
RRT initiation
showed benefit to
cognitive function
score and adverse
impact on burden
of kidney disease
and effects of
kidney disease
scores
Shum, 2014
(45)
Median survival
2.35 vs. 3.79 years
p < 0.001
Cox proportional
hazard ratio for
PD 0.46 (0.31–
0.68) adjusted for
age, comorbidities
and impairment in
activities of daily
living
Advantage lost in
high comorbidity
or if impaired daily
living
Greater hospital
days and
emergency
hospitalization in
CCC even after
adjustment for age,
comorbidity and
functional status
Less bothersome
intervention at end of
life and more renal
palliative care
p < 0.001
No difference in
institutionalization
Brown, 2015
(29)
Mean 20 vs.
33 months
Cause of Death was
more commonly
renal failure in
CCC than RRT
group
Various sub-group
analyses
If age >75 with ≥2
comorbidities
including coronary
disease or heart
failure, hazard
ratio for RRT 0.48
(0.21–1.09) [small
numbers]
Symptoms and
quality of life,
where reported
often stable or
improved with no
difference between
CCC and dialysis
Verberne,
2016 (46)
Median survival 1.5
vs. 3.1 years
Less difference in
age >80, age <70
with Davies
comorbidity score
>3 or if
cardiovascular
disease
Age, comorbidity
and mode
significant
Hazard ratio for
RRT vs. CCC 0.60
(0.42–0.92)
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Attitudes of Medical Staff, Patients, and their
Families to CCC
Given the lack of high-quality comparative out-
come data to guide decision-making, it is crucial to
understand how clinicians and patients view man-
agement options. Different patients may view the
same treatment in different ways and it is important
for clinicians to understand individual patients’
needs and how these may influence decisions. Quali-
tative research, aimed at exploring people’s views of
various life experiences, can help to unearth the
beliefs and expectations people hold regarding their
health, quality of life, and medical treatments.
A significant proportion of the qualitative litera-
ture has explored patients’ perceptions of choosing
between types of ESKF treatment, most frequently
between dialysis modalities, and living with dialysis.
Qualitative syntheses of this type of work have
highlighted that patients consider various aspects
when deciding what type of treatment is right for
them (49,50). Patients are seen to consider the effect
of treatment on their lifestyle and the impact on
family members. They can experience great uncer-
tainty when making treatment choices as they are
unclear how their CKD is likely to progress and
unsure about what different treatment approaches
can offer.
More recently, researchers have started to explore
patients’ views of nondialysis care. Five studies have
explored older patients’ reasons for choosing
nondialysis care (28,36,51–53). These indicate that
the perceived burden of dialysis is a common reason
why patients may choose nondialysis care. Patients
report that their age and functional ability make
attending dialysis sessions demanding and, as a con-
sequence, feel dialysis would negatively affect their
quality of life (51–53). Many older adults report dif-
ficulties in attending dialysis either because of avail-
ability of transport, time taken, or cost of travel
(51). Patients also feel that choosing dialysis may be
a burden on family members; interrupting their lives
or causing them emotional stress (28). Such practi-
calities can outweigh perceived benefit of dialysis
and those who feel they have lived a fulfilled life
may not want treatment that disrupts their way of
living (28,36,53).
When choosing nondialysis care patients most
often report feeling that they have made an
informed and autonomous decision (28,36). Patients
report having opportunities to discuss their options
with clinical staff and feel equipped to make deci-
sions (52). However, patients state that information
about dialysis is often given priority by staff and
that nondialysis care may be discussed little or not
at all (53). Decision aids and information leaflets
are likely to be heavily weighted toward dialysis
options, possibly reflecting the amount of evidence
in this area.
Interviews with individuals indicate that patients
may hold misunderstandings about CKD as a dis-
ease and what treatment can offer. Most often
patients are uncertain about how their disease will
progress and what this will mean for the future.
Some patients opting for nondialysis care report
feeling well, reporting no symptoms from their
CKD and as a result do not see the need for dialy-
sis (52,53). Patients can fail to recognize how their
CKD may progress and make treatment decisions
based on how they feel in the present rather than
on how they might feel in the future (51). This
could explain why some patients change their minds
and request dialysis once symptoms develop (53).
A small number of studies have explored clini-
cians’ views on how treatment decisions are made
with patients (20,54,55). Interviews with health pro-
fessionals have highlighted the difficulty nephrology
staff have in explaining CKD treatment and getting
patients to appreciate the severity of the disease
(20,54,55). Lack of public awareness of CKD and
its treatment are perceived to contribute to this.
Clinicians report additional challenges such as tai-
loring information to the educational level of the
patient, eliciting patient concerns about treatment
options and discussing options with patients who
fear dialysis after hearing the experiences of others
(54). Clinicians often report the importance of tim-
ing discussions so patients not only have enough
time to understand the information, but also intro-
ducing new material to patients gradually to avoid
anxiety (55).
Clinicians report that uncertainty about disease
progression makes it hard to advise patients on
management options and to prepare them for future
treatment (20,55). Uncertainty can lead to clinicians
avoiding discussions about the future; fearing that
information will be too negative for patients (55).
Discussions about prognosis or end of life may be
delayed until prompted by the patient or by illness
progression.
Only one study to date has specifically sought
clinicians’ views on nondialysis care (20). Clinicians
generally accepted it as an alternative to dialysis,
with most being grateful that they could offer some-
thing to patients if they did not choose dialysis.
Clinicians reported that discussing nondialysis
options with patients was a difficult task, more sui-
ted to experienced professionals because of the com-
plexity and sensitivity of end of life issues.
Clinicians felt more able to have these discussions
when they felt confident in talking about end of life
and in eliciting patient expectations. Such open dis-
cussions were felt to prevent misunderstandings and
patients changing their mind between treatment
options when symptoms developed at a later stage
(20). Similar qualitative work with clinicians focus-
ing on advanced care planning for patients with
CKD has also identified that staff may not view
such discussions as part of their role and that clini-
cal teams may not have a shared understanding of
advanced care planning (56). Research with patients
indicates that timely information regarding ACP
can help to support patient’s psychological needs
when undergoing treatment for ESKF (57).
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Components of Nondialysis Care
Patients who choose the nondialysis pathway are
generally pursuing a less disruptive approach to their
care (49). Balancing minimal therapeutic burden with
maximal symptom control requires an enhanced focus
on individualized goals, preferences, and values.
Ascertainment of these must be a routine component
of planning treatment. Clinicians who can elicit expec-
tations can correct misconceptions and help individu-
als understand how treatment options might impact
upon their quality and quantity of life. Practicalities
of treatment need to be considered alongside clinical
benefits in order for patients to frame decisions in
relation to their own lives. The organization of avail-
able nondialysis care is varied (19,20,56) and there is
no evidence available to identify best practice. Sys-
tems that encourage continuity of care and guidance
from multidisciplinary teams trained and experienced
in communication skills, shared decision-making, end
of life discussions, and advance care planning may be
best. Integration with primary and palliative care ser-
vices is needed.
The components of CCC are summarized
in Table 1 (18). However, all individuals with
advanced CKD need these components addressed and
ultimately it is preparation for and delivery of RRT
which delineates the care pathways. Given the evolv-
ing nature of disease and personal preferences, regular
review is needed to ensure treatment is aligned with
achievable goals. For some, this will involve move-
ment between the care pathways (Fig. 2). Many indi-
viduals will wish to concentrate on quality of life over
longevity. Others may value life extension more highly
and this stance is not discordant with nondialysis care
for those with a poor prognosis. Potential therapeutic
benefits are offset by treatment burdens, side effects,
and the competing risk of death.
The majority of patients in a nondialysis prepara-
tion phase will receive treatment undifferentiated
from routine CKD care. Those approaching end of
life and those who develop ESKF may choose to
reduce or stop treatment such as antihypertensives
that offer no immediate symptomatic benefit and a
low probability of life prolongation. Others will
decide to continue such treatment if they feel the
benefits outweigh the burdens. High quality shared
decision-making is needed to facilitate informed
choices. Treatment for patients on the nondialysis
pathway is summarized in Table 4.
The Future of Nondialysis Care—Conclusion
and Recommendations
Given the human and economic impact of dialy-
sis, there is a pressing need to establish the compar-
ative effectiveness and cost-effectiveness of RRT
and nondialysis care. It is incumbent on the
nephrology community to generate the best possible
evidence of person-centered health outcomes associ-
ated with each treatment approach and learn how
to present this evidence to patients in a way that
allows them to make decisions that are most appro-
priate for them. The following five recommenda-
tions are focussed on this aim.
1. Agreed definitions are required that clearly dis-
tinguish phases of treatment. A suggested
framework is proposed (Fig. 2).
2. Nondialysis care should be discussed early and
openly with patients approaching ESKF and
should feature more prominently in decision-
support materials.
3. Improved observational and organizational
research is needed to gain a better under-
standing of the natural history of advanced
CKD and ESKF and to identify the most
effective and efficient ways to deliver care
and monitor equity of care. This could be
achieved through a combination of extending
RRT registries to capture earlier stages of
CKD and by studying routine hospital and
primary care databases. Improved capture of
early dialysis outcomes and inclusion of
patients with CKD including those on CCC
(58) will improve data capture in areas
known to be deficient (Fig. 1). Auditable
standards and quality assurance data could
help to coordinate more consistent care at a
national level, and ensure equity of delivery.
4. The viability of a trial comparing the effective-
ness and cost-effectiveness of nondialysis and
RRT care pathways in individuals where clini-
cal equipoise exists should be investigated.
While practical and ethical intricacies make this
challenging, observational data may never be
able to separate unmeasured confounding by
indication from treatment effect.
5. Working with colleagues in primary care and
palliative medicine, the renal community must
continue to strive to improve dialysis outcomes
for older patients and those with multiple
comorbidities, including greater use of home
and assisted therapies. The benefits and risks of
RRT are not fixed and whatever evidence is
generated regarding nondialysis pathways will
need to keep pace with advances in practice.
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